ZZZhengkui Zhang

Zhengkui Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhengkui Zhang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Rutong Yu

    Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China

    5 shared publications
  • Jiaojiao Zhao

    Jiangsu Key Laboratory of Phylogenomics and Comparative Genomics, Jiangsu International Joint Center of Genomics, School of Life Sciences, Jiangsu Normal University, Xuzhou, China

    4 shared publications
  • Zhonghai Zhang

    Jiangsu Key Laboratory of Phylogenomics and Comparative Genomics, Jiangsu International Joint Center of Genomics, School of Life Sciences, Jiangsu Normal University, Xuzhou, China

    4 shared publications
  • Duo Xu

    Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China

    3 shared publications
  • Gaochuan Fang

    Jiangsu Key Laboratory of Phylogenomics and Comparative Genomics, Jiangsu International Joint Center of Genomics, School of Life Sciences, Jiangsu Normal University, Xuzhou, China

    3 shared publications
  • Shuo Ma

    Institute of Nervous System Diseases, Xuzhou Medical University, 84, West Huai-Hai Road, Xuzhou, 221002, China

    3 shared publications

Latest Publications

  • Open Access

    Relationship between cerebrospinal fluid neurobiomarkers and symptoms in older patients with cognitive impairment: an observational clinical study

    by Changshui Yu, Zhen Li, Haitao Chen, Da Zhang, Jia Gu, Yan Wang, Shuo Ma, Xingjun Li, Xiangwen Tang, Zhengkui Zhang, et al.

    This study was conducted to investigate cerebrospinal fluid neurobiomarker levels in elderly individuals with cognitive impairment and their correlation with clinical symptoms such as cognitive abilities, psychiatric symptoms, and self-care abilities. We collected data from 250 elderly patients suffering from cognitive impairment, with all participants being admitted to hospital. Neurobiomarker levels were tested by single-molecule immunoassay after cerebrospinal fluid specimens were obtained by lumbar puncture. Two trained neurologists jointly examined and questioned the rated patients, applying various scales. Aβ42, t-tau and p-tau181 not only affect elderly patients' cognition but also are correlated with neuropsychiatric symptoms (depression, anxiety), while α-synuclein (α-syn) is significantly associated with elderly patients' mental status such as anxiety and depression. Meanwhile, self-care ability is affected by the multiplicity of multiple biomarkers such as p-tau181, α-syn, and t-tau/Aβ42. This study reveals the associations between cerebrospinal fluid biomarkers and cognitive, psychiatric, and self-care symptoms in elderly individuals with cognitive impairment. Aβ, tau, and α-syn each have characteristic association patterns, providing biomarker references for clinical assessment. Longitudinal studies are still needed to verify causality and clinical translation value.

  • Open Access

    Dual-targeted manganese-doped carbon dots activate the cGAS–STING pathway and immunogenic cell death for potent glioblastoma immunotherapy

    by Zhen Li, Changshui Yu, Hongyu Che, Duo Xu, Dong Lu, Yan Wang, Xingjun Li, Shuo Ma, Xu Zhang, Zhengkui Zhang, et al.


  • Open Access

    Cascade reaction–driven biomimetic scintillant/metal–organic frameworks for X-ray triggered combinational therapy against glioma

    by Lansheng Wang, Duo Xu, Xudong Hu, Rui Quan, Dong Lu, Zhen Li, Changshui Yu, Xingjun Li, Shuo Ma, Xiaoming Li, et al.


  • Open Access

    Bioinformatics analysis of SH2D4A in glioblastoma multiforme to evaluate immune features and predict prognosis

    by Tian Yang, Chujun Li, Duo Xu, Rui Quan, Lansheng Wang, Yanhong Ren, Zhengkui Zhang, Rutong Yu

    Background: Glioblastoma multiforme (GBM) is the most common and aggressive primary brain cancer in adults. This study aimed to obtain data on immune cell infiltration based on public datasets and to examine the prognostic significance of SH2 domain containing 4A (SH2D4A) for GBM. Methods: SH2D4A expression in GBM was analyzed using a Tumor Immunity Estimation Resource (TIMER) 2.0 dataset, and a gene expression profile interaction analysis (GEPIA), and the results were validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The Chinese Glioma Genome Atlas (CGGA) dataset was used to assess the effect of SH2D4A on GBM patient survival. The SH2D4A co-expression network of the LinkedOmics dataset and GeneMANIA dataset was also investigated. Least absolute shrinkage and selection operator (LASSO) regression models and a nomogram were constructed to assess the prognosis of GBM patients. A Gene Set Enrichment Analysis (GSEA) was performed using The Cancer Genome Atlas (TCGA) dataset to find functional differences. The relationship between SH2D4A expression and tumor-infiltrating immune cells was analyzed using xCELL, the Cell Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) algorithm, and the TIMER dataset. Results: We discovered that SH2D4A expression was upregulated in GBM patients, and elevated SH2D4A expression was also substantially correlated with tumor grade. The survival curve analysis and multivariate Cox regression analysis showed that high SH2D4A expression was a significant independent predictor of poor overall survival (OS) in GBM patients. The immunoassay results suggested that altered SH2D4A expression may affect the immune infiltration of GBM tissues and thus the survival outcomes of GBM patients. Conclusions: In addition to being a possible prognostic marker and therapeutic target for GBM, SH2D4A may also accelerate the progression of GBM.

  • Decitabine suppresses MDSC-induced immunosuppression through dual functional mechanism and inhibits melanoma metastasis

    by Zhonghai Zhang, Tianlong Wang, Gaochuan Fang, Xufeng Xiao, Zhengkui Zhang, Jiaojiao Zhao

    Myeloid-derived suppressor cells (MDSCs) play a crucial role in promoting melanoma metastasis. Reprogramming MDSCs into mature M1 macrophages has emerged as a strategy to inhibit metastasis. Decitabine (Dec) is known to eradicate MDSCs and suppress tumor growth. In this study, we provide evidence that Dec not only reduces the MDSC population by inducing apoptosis, arresting cell cycle, and impairing recruitment, but also suppresses their immunosuppressive function by downregulating related genes and facilitating differentiation into M1 macrophages. Transcriptomic analysis of Dec-treated MDSCs revealed a marked downregulation of immunosuppressive genes including S100a9, S100a8, Vegf, Cxcr2, and Nos2. Meanwhile, M1 macrophage-associated genes involved in immune activation were upregulated, such as Ddx58, Isg15, Tap1, Ccl5, Cxcl9, and Cxcl10. Further bioinformatic analysis indicated that Dec promotes MDSC-to-M1 macrophage differentiation and activates innate immune pathways including NOD-like signaling to enhance anti-tumor immunity. Time-course studies implied that Dec upregulates myeloid transcription factor Irf7 to initiate MDSC differentiation and orchestrate the anti-tumor immune response. Collectively, our study unveils a novel dual-functional mechanism of Dec as both a cytotoxic agent reducing MDSCs and an inducer of their differentiation into M1 macrophages, thereby alleviating immunosuppression. This highlights Dec’s potential for clinical melanoma metastasis suppression.


  • Open Access

    Enhancing anti-angiogenic immunotherapy for melanoma through injectable metal–organic framework hydrogel co-delivery of combretastatin A4 and poly(I:C)

    by Xufeng Xiao, Yunuo Zheng, Tianlong Wang, Xiaoqing Zhang, Gaochuan Fang, Zhonghai Zhang, Zhengkui Zhang, Jiaojiao Zhao

    The interplay between vascularization and macrophage-induced immune suppression plays a crucial role in melanoma treatment. In this study, we propose a novel combination approach to combat melanoma by simultaneously inhibiting tumor vascularization and enhancing macrophage-mediated anti-tumor responses. We investigate the potential of combining combretastatin A4 (CA4), a vascular-disrupting agent, with poly(I:C) (PIC), an immunostimulatory adjuvant. This combination approach effectively suppresses melanoma cell proliferation, disrupts vascularization, and promotes macrophage polarization towards the M1 phenotype for melanoma suppression. To facilitate efficient co-delivery of CA4 and PIC for enhanced anti-angiogenic immunotherapy, we develop an injectable metal–organic framework hydrogel using Zeolitic Imidazolate Framework-8 (ZIF-8) and hyaluronic acid (HA) (ZIF-8/HA). Our findings demonstrate that ZIF-8 enables efficient loading of CA4 and enhances the stability of PIC against RNAase degradation in vitro. Furthermore, the developed co-delivery hydrogel system, PIC/CA4@ZIF-8/HA, exhibits improved rheological properties, good injectability and prolonged drug retention. Importantly, in vivo experiments demonstrate that the PIC/CA4@ZIF-8/HA formulation significantly reduces the dosage and administration frequency while achieving a more pronounced therapeutic effect. It effectively inhibits melanoma growth by suppressing angiogenesis, destroying blood vessels, promoting M1 macrophage infiltration, and demonstrating excellent biocompatibility. In conclusion, our study advances anti-angiogenic immunotherapy for melanoma through the potent combination of PIC/CA4, particularly when administered using the PIC/CA4@ZIF-8/HA formulation. These findings provide a new perspective on clinical anti-angiogenic immunotherapy for melanoma, emphasizing the importance of targeting tumor vascularization and macrophage-mediated immune suppression simultaneously.


  • Open Access

    ITGA1 Promotes Glioma Cell Proliferation and Affects Immune Cell Infiltration in Low‐Grade Glioma

    by Yanhong Ren, Jianchang Xu, Zhengkui Zhang, Rutong Yu

    Background: Low‐grade glioma (LGG) is a commonly occurring type of central nervous system cancer. Integrin α1 (ITGA1), a family member of integrins, is implied in the malignant development of cancers, but the fundamental role of ITGA1 has not been illustrated yet in glioma. This study aimed to evaluate the prognostic value of ITGA1.Methods: Correlations between ITGA1 and relevant clinical features were analyzed in the LGG datasets based on Chinese Glioma Genome Atlas (CGGA) and Tumor Genome Atlas (TCGA). Glioma clinical samples and glioma cell lines were identified at the level of mRNA and protein level by Western blot. Cox regression were developed to assess the involvement of ITGA1 expression in predicting survival in LGG patients. Application of GSEA enrichment analysis to reveal ITGA1‐mediated biological functions in LGG. Using TIMER 2.0 to analyze correlations between immune cell infiltration. In addition, ITGA1 high expression was analyzed for correlation with immune checkpoint‐related genes and cumulative survival time.Results: ITGA1 was significantly more expressed in LGG than in normal samples. Cox regression indicated that ITGA1 was a risk factor independently for prognosis in LGG patients. GSEA enrichment analysis indicated that ITGA1 was engaged in several immunomodulatory processes. ITGA1 expression was shown to be highly correlated with the immune score, stromal score, and estimate score in LGG. ITGA1 was significantly related to the immune checkpoint‐associated gene expression. In vivo experiments showed that overexpression of ITGA1 promoted glioma cell invasion.Conclusion: High ITGA1 expression is correlated with immune infiltration of the low‐grade tumor, leading to poor prognoses in LGG patients.


  • Immunologically active ferumoxytol-poly(I : C) nanomaterials inhibit metastatic melanoma by regulating myeloid-derived suppressor cell differentiation

    by Gaochuan Fang, Zhonghai Zhang, Bo Jiang, Yunuo Zheng, Xufeng Xiao, Tianlong Wang, Zhengkui Zhang, Jiaojiao Zhao

    Nanomaterials have been identified as a potential therapeutic option for targeting myeloid-derived suppressor cells (MDSCs), which are known to play a crucial role in tumor metastasis and treatment resistance. Here, we report a unique immunologically active nanomaterial composed of ferumoxytol and poly(I : C) (FP-NPs) and investigate its immunoregulatory activities on MDSCs in metastatic melanoma. In vivo assays demonstrated that FP-NPs had the ability to significantly impede the progression of metastatic melanoma and decrease the MDSC population in the lungs, spleen, and bone marrow of mice. Both in vivo and in vitro experiments revealed that FP-NPs reduced the number of granulocytic MDSCs and promoted the differentiation of monocytic MDSCs into anti-tumor M1 macrophages. Transcriptome sequencing indicated that FP-NPs significantly altered the expression of several genes involved in immunity. Analysis of Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and quantitative real-time PCR revealed that FP-NPs significantly increased the expression of the myeloid cell differentiation-related gene interferon regulatory factor 7 and activated interferon beta-related signaling pathways, which stimulated the differentiation of MDSCs into M1 macrophages. These findings suggest that FP-NPs, a unique nanomaterial with immunological properties, can induce MDSCs to differentiate into M1 macrophages, potentially offering new treatment prospects for metastatic melanoma in the future.


  • The combinational nano-immunotherapy of ferumoxytol and poly(I:C) inhibits melanoma via boosting anti-angiogenic immunity

    by Yunuo Zheng, Bo Jiang, Hongmei Guo, Zhonghai Zhang, Bo Chen, Zhengkui Zhang, Shaoyuan Wu, Jiaojiao Zhao